Sanctuary Advisors LLC Acquires 340,266 Shares of Kenvue Inc. (NYSE:KVUE)

Sanctuary Advisors LLC boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 166.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 544,890 shares of the company’s stock after acquiring an additional 340,266 shares during the quarter. Sanctuary Advisors LLC’s holdings in Kenvue were worth $13,121,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its holdings in shares of Kenvue by 34.9% during the second quarter. Assenagon Asset Management S.A. now owns 347,625 shares of the company’s stock worth $6,320,000 after purchasing an additional 89,896 shares during the period. Blue Trust Inc. lifted its holdings in Kenvue by 20.5% during the 2nd quarter. Blue Trust Inc. now owns 6,185 shares of the company’s stock worth $112,000 after buying an additional 1,054 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Kenvue by 9.1% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,216,574 shares of the company’s stock valued at $76,657,000 after buying an additional 351,999 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of Kenvue by 20.4% in the second quarter. First Horizon Advisors Inc. now owns 24,093 shares of the company’s stock valued at $438,000 after buying an additional 4,076 shares during the period. Finally, Chevy Chase Trust Holdings LLC raised its position in shares of Kenvue by 9.5% during the second quarter. Chevy Chase Trust Holdings LLC now owns 1,046,754 shares of the company’s stock worth $19,030,000 after acquiring an additional 91,056 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE KVUE opened at $22.21 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average price is $22.95 and its 200-day moving average price is $21.17. The firm has a market capitalization of $42.58 billion, a P/E ratio of 40.38, a P/E/G ratio of 2.02 and a beta of 1.36. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the prior year, the business earned $0.31 EPS. The firm’s revenue for the quarter was down .4% on a year-over-year basis. Equities research analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.69%. The ex-dividend date was Wednesday, November 13th. Kenvue’s payout ratio is currently 149.09%.

Analyst Ratings Changes

Several analysts recently commented on the company. JPMorgan Chase & Co. upped their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Bank of America lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $24.00 in a research report on Thursday. Finally, Piper Sandler lifted their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.